Crossmark

MYC in cancer: from undruggable target to clinical trials

Crossref DOI link: https://doi.org/10.1038/s41573-025-01143-2

Published Online: 2025-02-19

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Whitfield, Jonathan R. https://orcid.org/0000-0002-4925-7283
Soucek, Laura https://orcid.org/0000-0002-4750-7971
License Information

Text and Data Mining valid from 2025-02-19

Version of Record valid from 2025-02-19
More Information

Article History

Accepted: 17 January 2025

First Online: 19 February 2025

Competing interests

: J.R.W. is a shareholder in Peptomyc S.L. L.S. is co-founder, CEO and shareholder of Peptomyc S.L.